Floatz logo

Ava-6000 (Fap-Activated Doxorubicin Prodrug)

Urothelial Carcinoma

Avacta Life Sciences LtdSmall moleculePhase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
73/ 100

Competitive context

162 Active assets in the Urothelial Carcinoma cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Beijing Biotech
Phase 3BB
Cis-Diamminedichloroplatinum Ii
Nagoya University
Phase 3BB
Durvalumab
Alliance for Clinical Trials in Oncology
Phase 3BB
Pembrolizumab
Sutro Biopharma, Inc.
Phase 3BB
Enfortumab Vedotin (Fully Human Monoclonal Antibody Conjugated To A Cytotoxic Agent Monomethyl Auristatin E (Mmae) Targeting Nectin-4)
Vasgene Therapeutics, Inc
Phase 2/3BB

View all 50 →

Same molecule, other indications

Ava-6000 (Fap-Activated Doxorubicin Prodrug) is also rated in:

tumor of salivary glandActive
CC
Indicative · Phase 1
43 / 100
View asset →
ovarian carcinomaActive
CC
Indicative · Phase 1
41 / 100
View asset →
soft tissue sarcomaActive
CC
Indicative · Phase 1
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →